These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 28366905)

  • 21. Financial interests of patient organisations contributing to technology assessment at England's National Institute for Health and Care Excellence: policy review.
    Mandeville KL; Barker R; Packham A; Sowerby C; Yarrow K; Patrick H
    BMJ; 2019 Jan; 364():k5300. PubMed ID: 30651227
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ethics and opportunity costs: have NICE grasped the ethics of priority setting?
    McMillan J; Sheehan M; Austin D; Howell J
    J Med Ethics; 2006 Mar; 32(3):127-8. PubMed ID: 16507653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Can the NICE "end-of-life premium" be given a coherent ethical justification?
    Cookson R
    J Health Polit Policy Law; 2013 Dec; 38(6):1129-48. PubMed ID: 23974470
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Getting their say, or getting their way? Has participation strengthened the patient "voice" in the National Institute for Clinical Excellence?
    Quennell P
    J Manag Med; 2001; 15(3):202-19. PubMed ID: 11547580
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Priority setting and cardiac surgery: a qualitative case study.
    Walton NA; Martin DK; Peter EH; Pringle DM; Singer PA
    Health Policy; 2007 Mar; 80(3):444-58. PubMed ID: 16757057
    [TBL] [Abstract][Full Text] [Related]  

  • 26. An analysis of NICE's 'restricted' (or 'optimized') decisions.
    O'Neill P; Devlin NJ
    Pharmacoeconomics; 2010; 28(11):987-93. PubMed ID: 20936882
    [TBL] [Abstract][Full Text] [Related]  

  • 27. What do hospital decision-makers in Ontario, Canada, have to say about the fairness of priority setting in their institutions?
    Reeleder D; Martin DK; Keresztes C; Singer PA
    BMC Health Serv Res; 2005 Jan; 5(1):8. PubMed ID: 15663792
    [TBL] [Abstract][Full Text] [Related]  

  • 28. NICE's use of cost effectiveness as an exemplar of a deliberative process.
    Culyer AJ
    Health Econ Policy Law; 2006 Jul; 1(Pt 3):299-318. PubMed ID: 18634698
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Beyond accountability for reasonableness.
    Friedman A
    Bioethics; 2008 Feb; 22(2):101-12. PubMed ID: 18251770
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Conceptualizations of fairness and legitimacy in the context of Ethiopian health priority setting: Reflections on the applicability of accountability for reasonableness.
    Petricca K; Bekele A
    Dev World Bioeth; 2018 Dec; 18(4):357-364. PubMed ID: 28544136
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Are the UK systems of innovation and evaluation of medical devices compatible? The role of NICE's Medical Technologies Evaluation Programme (MTEP).
    Chapman AM; Taylor CA; Girling AJ
    Appl Health Econ Health Policy; 2014 Aug; 12(4):347-57. PubMed ID: 24934924
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pharmacopolitics and deliberative democracy.
    Rawlins MD
    Clin Med (Lond); 2005; 5(5):471-5. PubMed ID: 16268329
    [TBL] [Abstract][Full Text] [Related]  

  • 33. If You're a Rawlsian, How Come You're So Close to Utilitarianism and Intuitionism? A Critique of Daniels's Accountability for Reasonableness.
    Badano G
    Health Care Anal; 2018 Mar; 26(1):1-16. PubMed ID: 28332130
    [TBL] [Abstract][Full Text] [Related]  

  • 34. How should cost-effectiveness analysis be used in health technology coverage decisions? Evidence from the National Institute for Health and Clinical Excellence approach.
    Williams I; Bryan S; McIver S
    J Health Serv Res Policy; 2007 Apr; 12(2):73-9. PubMed ID: 17407655
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Priority-setting in healthcare: a framework for reasonable clinical judgements.
    Baerøe K
    J Med Ethics; 2009 Aug; 35(8):488-96. PubMed ID: 19644007
    [TBL] [Abstract][Full Text] [Related]  

  • 36. What's happening at NICE?
    Rawlins MD; Dillon A; Leng G
    Clin Med (Lond); 2013 Feb; 13(1):13-5. PubMed ID: 23472486
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Priority setting in kidney transplantation: a qualitative study evaluating Swedish practices.
    Omar F; Tinghög G; Carlsson P; Omnell-Persson M; Welin S
    Scand J Public Health; 2013 Mar; 41(2):206-15. PubMed ID: 23287398
    [TBL] [Abstract][Full Text] [Related]  

  • 38. NICE's Discounting Review: Clear Thinking on Rational Revision Meets Obstacle of Industrial Interests.
    O'Mahony JF; Paulden M; McCabe C
    Pharmacoeconomics; 2021 Feb; 39(2):139-146. PubMed ID: 33462758
    [TBL] [Abstract][Full Text] [Related]  

  • 39. The meaning of severity - do citizenś views correspond to a severity framework based on ethical principles for priority setting?
    Broqvist M; Sandman L; Garpenby P; Krevers B
    Health Policy; 2018 Jun; 122(6):630-637. PubMed ID: 29728287
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Priority setting at the micro-, meso- and macro-levels in Canada, Norway and Uganda.
    Kapiriri L; Norheim OF; Martin DK
    Health Policy; 2007 Jun; 82(1):78-94. PubMed ID: 17034898
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.